A systematic review and meta-analysis examined the effectiveness of immune checkpoint inhibitors (ICIs) in treating advanced/metastatic neuroendocrine neoplasms (NENs) using data from 10 studies involving 464 patients.
The overall response rate (ORR) was found to be 15.5%, significantly influenced by factors like tumor location, differentiation, and treatment type, with poorly differentiated tumors showing a higher ORR (22.7%) compared to well-differentiated ones (10.4%).
Despite the better response in poorly differentiated tumors, these had a negative effect on overall survival, indicating a complex relationship between treatment efficacy and tumor characteristics.